ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that registration with the U.S. National Institutes of Health – ClincialTrials.gov website has now gone ‘live’ confirming Lupuzor’s™ pivotal Phase III trial protocol and the current clinical commencement and completion of the study. Further details can be viewed at: ClincialTrials.gov For further details click here

The release as fetched from its publisher. immupharma.co.uk ↗